BOEHRINGER INGELHEIM USA CORPORATION

Lobbying client · District of Columbia · filed 2025 to 2026

Lobbyists

$5,535,000 Reported spend

6 Filings counted

1 Firms hired

11 Bills named

Spend is reported income plus in-house expenses across 6 filings. 2 further filings on this record were restated by a later amendment and are left out of every total here. Everything on this page is grouped by the client's LDA id (178410), not by name.

Firms hired 1

BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC $5,535,000 6 filings

Bills named in these filings 11

HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and bi…

6 filings
S 832
EPIC Act of 2025

6 filings
HR 8467
Farm, Food, and National Security Act of 2024

5 filings
HR 1842
PAW Act of 2025

4 filings
HR 3419
Foreign Animal Disease Prevention, Surveillance, and Rapid Response Act of 2023

3 filings
S 1666
Foreign Animal Disease Prevention, Surveillance, and Rapid Response Act of 2023

3 filings
HR 842
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act

3 filings
HR 946
ORPHAN Cures Act

3 filings
S 1862
ORPHAN Cures Act

3 filings
S 339
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act

3 filings
HR 7567
Farm, Food, and National Security Act of 2026

1 filing

Reported by year 2 years

2026 $1,875,000 2 filings
2025 $3,660,000 4 filings

Issues lobbied 4

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 5

Agriculture, Dept of (USDA) 6
Centers For Medicare and Medicaid Services (CMS) 6
Environmental Protection Agency (EPA) 6
HOUSE OF REPRESENTATIVES 6
SENATE 6

Recent filings 8 total

Q2

BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $710,000 expenses · posted Jul 20, 2026

View → Q1

BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC

1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $1,165,000 expenses · posted Apr 20, 2026

View → 2A

BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC

2nd Quarter (Apr 1 - June 30) 2025 · House · Senate · $990,000 expenses · posted Mar 10, 2026

View → 4A

BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC

4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $610,000 expenses · posted Feb 4, 2026

View → Q4

BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC Amended

4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $580,000 expenses · posted Jan 20, 2026

View → Q3

BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC

3rd Quarter (July 1 - Sep 30) 2025 · House · Senate · $820,000 expenses · posted Oct 20, 2025

View → Q2

BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC Amended

2nd Quarter (Apr 1 - June 30) 2025 · House · Senate · $990,000 expenses · posted Jul 21, 2025

View → Q1

BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC

1st Quarter (Jan 1 - Mar 31) 2025 · House · Senate · $1,240,000 expenses · posted Apr 21, 2025

View →

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.